Fetal risk associated with rubella vaccine

Area of Science:

• Immunology
• Vaccinology
• Teratology

Background:

• Congenital rubella syndrome (CRS) is a significant public health concern.
• Rubella vaccination is crucial for preventing CRS in women of childbearing age.
• Concerns exist regarding the potential teratogenic effects of live rubella vaccines on the fetus.

Purpose of the Study:

• To assess the safety of different rubella vaccine strains in pregnant women.
• To determine the risk of congenital malformations following rubella vaccination during pregnancy.

Main Methods:

• Observational study involving 112 women of childbearing age who received various rubella vaccines (Cendehill, HPV-77, RA 27/3, unknown strain).
• Infants were monitored for abnormalities compatible with congenital rubella.
• Maternal immune status was assessed at the time of vaccination.

Main Results:

• All infants born to mothers vaccinated with Cendehill or HPV-77 (n=94) were healthy.
• No abnormalities compatible with CRS were observed in infants born to mothers vaccinated with RA 27/3 (n=17) or those with unknown immune status (n=54).
• The maximum estimated risk for severe congenital malformations was approximately 3% across all cases.

Conclusions:

• Rubella vaccination of women of childbearing age poses a low risk of severe congenital malformations.
• Concerns about fetal adverse effects should not deter vaccination in this population.
• Pregnant women should not receive rubella vaccine, and conception should be postponed for three months post-vaccination.